Previously, it has been observed that fL-opioid receptors contribute to while K-opioid receptors oppose pial artery dilation in response to hypoxia. The present study was designed to investigate the contribution of 5 1and 52-opioid receptor activation to hypoxia-induced pial vasodilation. Newborn pigs equipped with a closed cra nial window were used to measure pial artery diameter and collect cortical periarachnoid CSF for assay of opio ids. Hypoxia increased CSF leucine enkephalin (a 5-ago nist) from 36 ± 6 to 113 ± 17 pg/ml (n = 5). Hypoxia induced pial artery vasodilation was attenuated during moderate hypoxia (Pa02 = 35 mm Hg), while this re sponse was blunted during severe hypoxia (P a02 = 25 mm Hg), by the 5 1-opioid receptor antagonist 7-benzylidenen altrexone (BNTX; 10-8 M) (23 ± 2 vs. 13 ± 2 and 34 ± 539 oxia, but only attenuated the vasodilator response during severe hypoxia (22 ± 2 vs. 8 ± 2 and 33 ± 4 vs. 23 ± 4% for moderate and severe hypoxia in the absence and pres ence of naltrindole, respectively; n = 5). Receptor selec tivity experiments show that BNTX blocked responses to the 5 1-agonist DPDPE, whereas responses to the 52agonist deltorphin II were unchanged (12 ± 3 vs. 2 ± 1% and 14 ± 4 vs. 14 ± 3% for DPDPE at 10-6 M and del torphin II at 10-6 M in the absence and presence of BNTX; n = 5). Similarly, naltrindole blocked responses to deltorphin II, but responses to DPDPE were un changed. These data indicate that 5 1-receptor activation contributes to both moderate and severe hypoxia-induced vasodilation, but the 5 1-receptors appear to be more im portant during severe hypoxia relative to 52-receptors. Additionally, these data show that 52-receptors primarily contribute to dilation during moderate hypoxia.
6 vs. 10 ± 3% for moderate and severe hypoxia in the absence and presence of BNTX, respectively; n = 5). In contrast, the 52-opioid receptor antagonist naltrindole (10-9 M) blunted pial vasodilation during moderate hyp-Several mechanisms have been proposed to ac count for hypoxia-induced cerebral vasodilation. These possibilities include adenosine, prostaglan dins, and nitric oxide (Winn et ai., 1981; Iwamoto et ai., 1992; Coyle et ai., 1993) . Most studies, how ever, have investigated mechanisms involved in hypoxic cerebrovasodilation in the adult; mecha nisms involved in hypoxic cerebrovasodilation in the newborn/infant period have received little atten tion. Indirect evidence suggests opioid involvement in hypoxic cerebrovasodilation in the newborn. For example, it was observed that hypoxia increases plasma methionine enkephalin in fetal sheep (Mar tinez et ai., 1990) and plasma l3-endorphin in human newborns at delivery (Wardlaw et ai., 1979; Mar tinez et ai., 1991) and in those infants with hypoxic ischemic encephalopathy with ongoing hypoxia (Sankaran et ai., 1983) . More recently, it has been observed that hypoxia increases cortical periarach noid CSF methionine enkephalin and dynorphin concentration in the newborn pig (Armstead, 1995) . Results from that study further indicate the f,L-opi oid receptor activation (methionine enkephalin) contributes to while K-opioids (dynorphin) oppose hypoxia-induced pial artery vasodilation. However, the role of o-opioid subtypes and their relative con tribution to pial artery vasodilation during levels of hypoxia are uncertain.
Opioids contribute to the regulation of cerebral hemodynamics. Opioid receptor binding has been demonstrated on cerebral microvessels (Peroutka et aI., 1980) . Enkephalin and dynorphin immunoreac tivities have been shown in large cerebral arteries of the pig (Thureson-Klein et aI., 1989) . Moreover, CSF opioid concentrations are in the vasoactive range in the newborn pig during resting conditions (Armstead et aI., 1991) . Previously, opioids such as methionine enkephalin and leucine enkephalin have been observed to produce cerebral vasodilation, while others (e.g., /3-endorphin) elicit vasoconstric tion (Armstead et aI., 1991) . Dynorphin produces tone-dependent effects (dilation normotension; va soconstriction during hypotension) (Armstead et aI., 1991) .
The present study was designed to investigate the contribution of 51-and 52-opioid receptor activation to pial artery vasodilation in response to moderate and severe hypoxia.
METHODS
Newborn pigs (1-5 days old) of either sex were used in these experiments. They were sedated with ketamine hy drochloride/acepromazine (33 mg/kg i.m.). Anesthesia was maintained with a-chloralose (30-50 mg/kg initially, supplemented with 5 mg/kg/h i.v.). A catheter was in serted into a femoral artery to record blood pressure and to sample for blood gases and pH. Another catheter was placed in a femoral vein for injection of drugs. The tra chea was cannulated, and the animals were ventilated with room air. Body temperature was monitored via a rectal temperature probe and maintained at 37-38°C with a heating pad.
For insertion of the cranial window, the scalp was re moved and an opening was made in the skull over the parietal cortex. The dura was cut and retracted over the cut bone edge. The cranial window was placed in the hole and cemented in place with dental acrylic. The space un der the window was filled with artificial CSF of the fol lowing composition (mg): 220 KCI, 132 MgCI2, 221 CaCI2, 7, 710 NaC!, 402 urea, 665 dextrose, and 2, 066 NaHC031 L, with pH 7.33, Pc02 46 mm Hg, and P02 43 mm Hg. Pial arterioles were observed with a dissecting micro scope, a television camera mounted on the microscope, and a video monitor. Vascular diameter was measured with a video microscaler (model VPA 550; For-A-Corp, Los Angeles, CA, U.S.A.).
Protocol
Pial artery diameter (small artery 120-160 fLm; arteriole 50-70 fLm) was determined every minute for a lO-min exposure period after injection under the window of arti ficial CSF containing no drug and after injection of CSF containing drug. Diameters were also measured 10-15 min after the highest concentration of a drug was flushed off the cerebral cortical surface with CSF containing no drug. Typically, 1-2 ml of CSF was flushed through the window over 30 s. Needles incorporated into the side of the window allowed infusion of CSF under the window and runoff of excess CSF. We measured the peak re sponse, and a CSF sample for opioid analysis was col lected at the end of the 10-min exposure period. Cerebral J Cereb Blood Flow Metab. Vol. 15, No.3, 1995 cortical periarachnoid CSF (300 fL!) was collected by slowly infusing artificial CSF into one side of the window and allowing the CSF under the window to drip freely into a collection tube on the opposite side.
Hypoxia was produced by decreasing inspired O2 suf ficiently to reduce and maintain P a02 at either 36 ± 2 or 26 ± 2 mm Hg while maintaining constant P ac02' Changes in pial artery diameter were noted every minute during a lO-min hypoxic exposure period. A blood sample con firming the hypoxic challenge was taken 3 min after the exposure period was begun. Once blood chemistry data confirmed that the desired level of hypoxia had been achieved, peak dilator responses were recorded. Re sponses to hypoxia were obtained before and after 7-ben zylidenenaltrexone (BNTX; 10-8 M) and naltrindole (10-9 M) (Research Biochemical, Natick, MA, U.S.A.).
The receptor selectivity of the opioid receptor antagonists was assessed by obtaining responses to methionine en kephalin, leucine enkephalin, dynorphin, �-endorphin (fL-, 8-, K-, and E-receptor agonists, respectively, 10-8, 10-6 M; Sigma Chemical Co., St. Louis, MO, U.S.A.), DAMGO, DPDPE (10-8, 10-6 M; RBI), and deltorphin II (10-8, 10-6 M) (Bachem, Torrance, CA, U.S.A.) be fore and after BNTX and naltrindole. Time control ex periinents were designed to compare initial responses to agonists with those obtained 30 min later.
Appropriate aliquots of the vehicle for all agents (0.9% saline) were added to CSF infused under the window. The CSF vehicle had no effect on arteriolar diameter (e.g., 136 ± 10 vs. 134 ± 12 fLm; n = 5). All working drug solutions were made fresh on the'day of use.
Opioid analysis
CSF samples collected were immediately acidified with 1 N acetic acid to prevent peptide degradation, rapidly frozen, and stored at -20°C. Radioimmunoassay kits for leucine enkephalin are commercially available (Penin sula, Belmont, CA, U.S.A.). The radioimmunoassay uses simultaneous addition of sample, rabbit anti-opioid anti body, and the 1 2 51 derivative of the opioid. After an over night incubation at 4°C, free opioid was separated from opioid bound to antibody by the addition of saturated ammonium sulfate in the presence of rabbit carrier ,(-globulin. Following centrifugation at 760 g for 10 min, the supernate was decanted and the pellet counted using a ,(-scintillation counter. All samples and standard were assayed in duplicate. Data are calculated as % BIBo vs. concentration, where % BIBo = (avg. cpm of sampleavg. cpm of non-specific binding tube)IBo x 100 and Bo = avg. cpm of total binding tube -avg. cpm of non-specific binding tube. We have used these methods previously to quantify opioid concentration in periarachnoid cortical CSF (Armstead et aI., 1991) .
Statistical analysis
Pial arteriolar diameter, systemic arterial pressure, and opioid levels were evaluated using analysis of variance for repeated measures and t test where appropriate. If the value was significant, the Fisher test was performed. An a level of p < 0.05 was considered significant in all sta tistical tests. Values are presented as means ± SD of absolute values or as percentages of change from control values. Data presented as percent change were compared by nonparametric means using the Wilcoxon signed rank test.
RESULTS

Influence of hypoxia on cortical periarachnoid CSF opioid concentration
Hypoxia significantly increased CSF leucine en kephalin by 3.1 ± 0.2-and 3. 8 ± 0.5-fold during moderate (P a02 = 35 mm Hg) and severe (P a02 = 25 mm Hg) hypoxia, respectively ( Fig. 1 ; n = 5).
Influence of opioid receptor antagonists on hypoxia-induced pial artery vasodilation
Moderate and severe levels of hypoxia elicited reproducible pial small artery (120-160 fLm) and ar teriole (50-70 fLm) vasodilation (Table 1 ; n = 5).
Hypoxia-induced dilation of small pial arteries and arterioles was attenuated by topical BNTX (10-8 M), a 5cantagonist, during moderate hypoxia and blunted by BNTX during severe hypoxia ( Fig.  2 ; n = 5). On a percentage basis, BNTX attenuated moderate hypoxia-induced small pial artery and ar teriole dilation by 43 ± 2 and 50 ± 9%, whereas severe hypoxia-induced dilation was decreased by 72 ± 12 and 69 ± 9% for small arteries and arteri oles, respectively. In contrast, the 52-opioid recep tor antagonist naltrindole (10-9 M) blunted pial va sodilation during moderate hypoxia, but only atten uated the vasodilator response during severe hypoxia ( Fig. 3 ; n = 5). On a percentage basis, naltrindole blunted moderate hypoxia-induced small pial artery and arteriole dilation by 64 ± 7 and 59 ± 6%, but only attenuated severe hypoxia induced dilation by 33 ± 9 and 29 ± 18% for small arteries and arterioles, respectively. while vascular responses to methionine enkephalin, dynorphin, and �-endorphin were unchanged (Figs. 4 and 5; n = 5). Since these naturally occurring opioids may interact with several opioid receptor subtypes, synthetic analogues were used to assess the selectivity of these antagonists. DPDPE and deltorphin II, 5)-and 52-opioid receptor agonists, respectively, elicited reproducible small artery and arteriole dilation ( dilation for DAMGO at 10-6 M in the absence and presence of either BNTX at 10-8 M or naltrindole at 10-9 M, n = 3). Finally, these concentrations for the 0 1 -and O2opioid receptor antagonists were chosen based on dose-response curves for their actions on 01-and 02-agonists. For DPDPE and deltorphin (10-6 M) responses with varying 00-9-10-7 M) BNTX con centrations, these data were as follows: DPDPE 12 ± 1, 9 ± 2, 2 ± 1, 1 ± 1% dilation and deltorphin 14 ± 2, 14 ± 3, 14 ± I, and 8 ± 1% dilation forO, 10-9, 10-8, and 10-7 M BNTX, respectively, n = 3. For DPDPE and deltorphin (10 -6 M) responses with varying naltrindole (10-1 0 _ 10 -8 M) concentrations, the data were as follows: DPDPE 9 ± 1, 9 ± 2, 9 ± 2, 3 ± 2% dilation and deltorphin 11 ± 1, 8 ± 2, 1 ± 2, 1 ± 2% dilation for 0, 10-1 0 , 10-9, and 10-8 M naltrindole, respectively, n = 3. Influence of opioid receptor antagonists on pial artery diameter BNTX (10-8 M) had no effect on pial small artery or arteriole dIameter (141 ± 16 vs. 141 ± 16 and 51 ± 6 vs. 53 ± 6 f.Lm for control and BNTX, respec tively; n = 5). Similarly, naltrindole (10 -9 M) had no effect on pial vessel diameter 048 ± 6 vs. 151 ± 10 and 60 ± 9 vs. 58 ± 7 f.LITl for control and nal trindole, respectively; n = 5).
Blood chemistry
Blood chemistry values were obtained at the be ginning and at the end of all normoxia experiments as well as during normoxia and hypoxia in experi ments designed to investigate the cerebrovascular effects of hypoxia (Table 3) . Hypoxia decreased Po2, while Pc02, pH, and mean arterial blood pres sure were unchanged.
DISCUSSION
Results of the present study show that (a) hypox ia increased cortical periarachnoid CSF leucine en kephalin concentration; (b) hypoxia-induced pial ar tery vasodilation was attenuated during moderate hypoxia; while this response was blunted during se vere hypoxia by the oj-opioid receptor antagonist BNTX; and (c) the 02-opioid receptor antagonist naltrindole blunted pial vasodilation during moder ate hypoxia, but only attenuated the vasodilator re sponse during severe hypoxia. These data indicate that oj-receptor activation contributes to both mod erate and severe hypoxia-induced vasodilation, but that oJ-receptors appear to be more important dur ing severe hypoxia relative to 02-receptors. Addi tionally, they show that 02-receptors primarily con tribute to dilation during moderate hypoxia.
The present study also characterized the opioid receptor selectivity of the probes used in these ex periments designed to investigate the role of opioids in hypoxia-induced pial artery dilation. Although they can interact with several opioid receptor sub types, the naturally occurring opioids methionine enkephalin, leucine enkephalin, dynorphin, and l3-endorphin are thought to be fl-, 0-, K-, and f-re ceptor agonists, respectively (Feuerstein and Siren, 1987) . With use of both these naturally occurring opioids and the synthetic agents DPDPE and del torphin II, selective oJ-and 02-agonists, respec tively (Jiang et al., 1991; Mattia et al., 1991) , BNTX blocked DPDPE and attenuated leucine enkepha lin-induced pial dilation, while responses to the other opioids were unchanged, consistent with this agent being a oJ-opioid receptor antagonist, as re ported previously (Sofuoglu et al., 1993) . Similarly, data from the present study show that naltrindole is a selective 02-opioid receptor antagonist (Sofuoglu et al., 1991) . Additionally, it is indicated that leu cine enkephalin interacts with both oJ-and 02-opioid receptors. Finally, these data show that BNTX and naltrindole have no effect on pial artery diameter by themselves, indicating that there is little o-opioid dependent vascular tone in the newborn cerebral circulation under resting conditions. Recent evidence supports the existence of sub types for the o-receptor, with at least two subtypes thus far hypothesized. The existence of o-receptor subtypes has been based mainly on antinociceptive and cross-tolerance studies (Jiang et al., 1991; Mat tia et al., 1991) . More recent data from binding and electrophysiological studies suggest that these o-re ceptor subtypes are distinct receptor entities (Negri et al., 1991; Watson and Lanthorn, 1993) . On this basis, subtypes of o-opioid receptors were sug gested to exist and termed the "oJ-receptor" (DPDPE sensitive) and the "02-receptor" (deltor phin II sensitive) (Mattia et al., 1991) . At the same time, using a different approach, Takemori and col- leagues arrived at similar conclusions concerning o-receptor subtypes in the mouse brain using o-re ceptor antagonists such as naltrindole (Portoghese et ai. , 1988; Sofuoglu et ai. , 1991) . However, the cardiovascular actions of o-opioid receptor agonists have received limited attention. Results of the present study, therefore, are the first to character ize the effects of selective o-opioid receptor ago nists in the newborn cerebral circulation. Previous research found that other opioids con tribute to the regulation of the newborn cerebral circulation. For example, methionine enkephalin and leucine enkephalin produce pial vasodilation, while [3-endorphin elicits vasoconstriction (Arm stead et ai. , 1991) . Dynorphin, on the other hand, produces tone-dependent effects (dilation during normotension, vasoconstriction during hypoten sion) (Armstead et ai. , 1991) .
The CSF is a dynamic milieu capable of reflecting normal and pathologic processes. Opioids in CSF could therefore be used as an index of secondary cerebrovascular events subsequent to induction of hypoxia. Recently, this laboratory has observed that hypoxia increased CSF methionine enkephalin and dynorphin concentrations (Armstead, 1995) . Additionally, these studies showed that hypoxia induced pial artery vasodilation was attenuated by [3-funaltrexamine, a fL-opioid receptor antagonist, but potentiated by norbinaltorphimine, a K-antago nist, indicating that fL-opioid receptor activation contributes to but that K-opioid receptors oppose, hypoxia-induced pial vasodilation. Data from the J Cereb Blood Flow Metab, Vol. 15, No.3, 1995 present study extend these earlier observations and correlate changes in CSF leucine enkephalin with hypoxic dilation. These data indicate that o-recep tor activation also contributes to hypoxia-induced pial dilation. Possible sources of these opioids in clude cortical vessels, nerves associated with these vessels, neurons, or glia. However, their origin can not be determined from the present experiments.
Several studies have examined the role of NO in hypoxic cerebrovasodilation. NO synthase inhibi tors have been reported to attenuate the increase in cerebral blood flow and pial artery dilation elicited by hypoxia in the adult (Iwamoto et ai. , 1992) . Hyp oxia relaxed isolated newborn cerebral vessels (Pearce and Ashwal, 1987) , and recently NO has been observed to contribute to hypoxia-induced pial artery dilation in the newborn pig (Armstead, 1995) . Since sodium nitroprusside (SNP), a direct releaser of NO, increases CSF methionine enkeph alin 'concentration (Armstead, 1995) , NO may also indirectly contribute to hypoxia-induced pial artery dilation via the release of dilator opioids. On the other hand, NO synthase inhibitors have also been reported to have no effect on hypoxia-induced cere brovasodilation in both the adult rat (Pelligrino et ai. , 1993) and the newborn pig (!chord et ai. , 1994) . Such controversial findings could be due to differ ences in methodology, type and dose of NO syn thase inhibitor used, and species differences.
Other mechanisms have been proposed to ac count for hypoxia-induced cerebral vasodilation. For example, considerable evidence indicates that adenosine contributes to cerebral vasodilation in re sponse to hypoxia in the adult (Emerson and Ray mond, 1981; Winn et ai. , 1981) . In the newborn, in contrast, the role of adenosine in regulating cerebral blood flow during hypoxia is less certain. In new born pigs, for instance, hypoxia increased brain in terstitial fluid adenosine concentration (Park et ai. , 1987) , but hypoxia-induced hyperemia was not di minished by theophylline (McPhee and Maxwell, 1987) . Similar differences concerning the role of prostaglandins in hypoxia-induced cerebrovasodila tion have also been noted. For example, indometh acin did not alter the hypoxic vasodilation in the adult cat or rat (Sakabe and Siesj6, 1979; Wei et ai. , 1980) , but attenuated hypoxic hyperemia in the newborn pig (Coyle et ai. , 1993) . Additionally, ac tivation of ATP-sensitive K + channels has recently been suggested to be involved in hypoxia-induced cerebral hyperemia and dilation of pial arteries (Reid et ai. , 1993; Taguchi et ai. , 1994) . Finally, vasopressin elicits pial vessel dilation in the new born (Armstead et ai. , 1989) and appears to contrib ute to hypoxia-induced cerebral vasodilation in fetal sheep (Eisenach et aI. , 1992) . Taken together, these observations indicate that several mechanisms probably contribute to hypoxia-induced cerebrova sodilation.
In addition to interacting with NO, opioid inter actions with other vasoactive systems could con tribute to hypoxia-induced pial vasodilation. For example, opioids increase CSF prostaglandin con centration (Armstead et aI. , 1990) , and the pros taglandins subsequently released have been sug gested to contribute to hypoxia-induced cerebrova sodilation (Coyle et ai. , 1993) . Additionally, prostaglandin 12 mediates the ability of dynorphin to increase CSF vasopressin (Armstead et aI. , 1992) ; vasopressin has also been suggested to contribute to hypoxia-induced cerebrovasodilation (Eisenach et aI. , 1992) . However, vasopressin elicits tone dependent effects (vasodilation during normoten sion, vasoconstriction during conditions that de crease cerebrovascular tone) (Armstead et al. , 1989) . Since hypoxia elicits pial vasodilation and therefore decreases cerebrovascular tone, vaso pressin may either contribute to or blunt hypoxia induced vasodilation. Therefore, opioids, pros taglandins, and vasopressin appear to interact in a coordinated fashion in their contribution to hypox ia-induced dilation.
In conclusion, data from the present study indi cate that 8-opioid receptor activation contributes to hypoxia-induced pial artery vasodilation.
